Innovair Nexthaler

Beclometasone dipropionate / formoterol fumarate, the active ingredient in Innovair Nexthaler, is an inhaled corticosteroid/long‑acting beta2‑agonist combination presented as a dry‑powder inhaler for inhalation use. It provides maintenance therapy for asthma and chronic obstructive pulmonary disease (COPD) in adult patients. It is indicated for regular use to improve lung function and reduce exacerbations.

GNH USA supplies Innovair Nexthaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for each shipment.

Innovair Nexthaler combines an inhaled corticosteroid with a long‑acting β2‑agonist to treat airway diseases.

- Asthma: improves symptom control and reduces the risk of severe attacks. - Chronic obstructive pulmonary disease (COPD): helps maintain airflow and decreases symptom frequency. - Maintenance therapy: reduces the frequency of exacerbations in chronic respiratory conditions.

Common Side Effects: - Throat irritation or soreness. - Oral candidiasis (thrush). - Hoarseness of voice.

Serious or Rare Side Effects: - Paradoxical bronchospasm. - Adrenal suppression with prolonged high‑dose use. - Severe allergic reaction, including anaphylaxis.

Before initiating therapy, consider the following precautions: - Assess for active respiratory infections: treat infection before use. - Monitor for oral candidiasis: advise rinsing mouth after inhalation. - Evaluate cardiac history: caution in patients with arrhythmias. - Use the lowest effective dose to achieve control. - Educate on proper inhaler technique to minimize local irritation. - Store at ambient temperature: keep in original container, protect from moisture and heat.

Major Interactions (Avoid): - Non‑selective β‑blockers: may blunt bronchodilator effect. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase corticosteroid exposure. - Diuretics: may enhance hypokalemia risk.

Moderate Interactions (Monitor Closely): - Theophylline: may increase risk of tachycardia. - Ritonavir and other protease inhibitors: may raise systemic steroid levels. - Anticholinergic bronchodilators: monitor for additive bronchial effects.